







# AWTTC Work Programme 2025-2028

Objective	Impacted by VPAG*?	Intended outcome	
 <b>Horizon scanning and financial forecasting</b>			
1	Undertake a mapping exercise across Wales to determine the current horizon scanning/financial forecasting landscape, identify any gaps, duplications and barriers, and scope potential solution.	✓	Understand the requirements of stakeholders to inform the development of an enhanced horizon scanning and financial forecasting service for Wales.
2	Develop an action plan based on the results of the mapping exercise to support development of the national horizon scanning and financial forecasting service for Wales.	✓	The key tasks required to support the development of the horizon scanning and financial forecasting processes will be defined and prioritised.
3	Develop horizon scanning and financial forecasting methods, processes, outputs and reporting mechanisms.	✓	Reporting using the AWTTC medicines access database will be developed and refined so that all stakeholders are provided with sufficient horizon scanning and financial forecasting information. This will assist health boards and trusts with service and budget planning and provide information on a 'Once for Wales' basis.
4	Monitor pipeline medicines.		To support service planning and financial forecasting, enabling the NHS in Wales to be better prepared and provide timely access to clinically and cost-effective medicines.
 <b>Medicines ecosystem</b>			
5	Develop processes and new systems to address current gaps in advice for Wales outside of NICE Technology Appraisal guidelines.	✓	People in Wales have timely access to medicines where there is a unmet clinical need (right people, right time, right medicines).
6	Input into national collaborations on medicine access.	✓	Align processes and systems and identify areas for collaboration to improve efficiency, reduce duplication and deliver robust evidence-based advice.
7	Deliver medicines assessments.	✓	People in Wales have timely access to medicines where there is an unmet clinical need.

\* VPAG = Voluntary Scheme for Branded Medicines Pricing, Access, and Growth. Find out more here: [VPAG \(Wales\) Investment Programme – AWTTC.nhs.wales](https://www.nhs.uk/awttc/vpag/)

Objective	Impacted by VPAG*?	Intended outcome	
 <b>Implementation of medicines</b>			
8	Enhance the processes and mechanisms managed by the Commercial Medicines Access Team (CMAT) to ensure that there are robust processes in place to facilitate timely access to medicines associated with a commercial arrangement. To ensure health boards and trusts in Wales can access and receive the maximum possible value for money for NICE and AWMSG approved medicines.	✓	Ensure the NHS in Wales gets the medicines for the right price so that the right people receive clinically and cost-effective treatments at the right time.
9	Implement the Blueteq High-Cost Drugs (HCD) system to enhance clinical and financial governance of high-cost medicines, providing health boards and trusts in NHS Wales with a standardised process to reduce variation in access to medicines and improve access to data.	✓	Better governance and monitoring of high cost drug usage across Wales, reducing variation in prescribing across health boards and trusts and providing data to support clinical decision making, patient safety and commercial access.
10	Develop a process for supporting the planning and introduction of new medicines and monitoring the uptake of high-impact medicines, e.g. national pathways mapping of complex/novel therapies.	✓	Provide an 'All Wales' approach to the planning and introduction of AWMSG and NICE approved medicines, supporting the consistent uptake of medicines likely to have a significant impact on existing services and/or clinical pathways.
11	Supporting access to new treatment fund medicines.	✓	People (patients & health care professionals) have timely and equitable access to clinically and cost-effective medicines.
 <b>Data</b>			
12	Collaborate with DHCW to access new data sets including those within the National Data Resource (NDR) and the Digital Medicines Transformation Portfolio (DMTP), which will support, safe, efficient, and effective prescribing for patients and healthcare professionals.	✓	AWTTTC collaborates with DHCW and other stakeholders in providing meaningful benefits from new datasets.
13	Establish new data sets to enable identification of unwarranted variation in prescribing.	✓	Prescribing outliers are identified for health board investigation to achieve positive change. These data will include outcome/real-world evidence where possible.

\* VPAG = Voluntary Scheme for Branded Medicines Pricing, Access, and Growth. Find out more here: [VPAG \(Wales\) Investment Programme – AWTTTC.nhs.wales](https://www.awttc.nhs.uk/vpag)

Objective		Impacted by VPAG*?	Intended outcome
14	Utilise existing and new data to support decision making in medicines optimisation.	✓	Datasets are explored by AWTTTC to develop beneficial analyses and visualisations and provide insights for stakeholder utilisation.
15	Produce regular and ad hoc data reports.		Stakeholders have access to information when they need it.
16	Maintain data sources and SPIRA.		Stakeholders have access to information when they need it and SPIRA remains accessible and fit for purpose.
	<b>Medicines optimisation</b>		
17	Develop and implement a governance structure and programme of work for Your Medicines, Your Health.		To support the public and HCPs in ensuring that patients in Wales take their medicines in a way that maximises their health outcomes, and that waste associated with medicines use is reduced and sustainability is improved.
18	Review and update the AWTTTC Medicines Optimisation Framework.		Processes for how we prioritise our work and develop each of our outputs are more transparent and continue to be fit for purpose.
19	Develop and publish the 2029-2031 set of National Prescribing Indicators.		A new set of NPIs is developed that reflects the priorities of NHS Wales and continues to drive rational prescribing.
20	Deliver medicines optimisation resources.		Stakeholders continue to have access to resources that meet their needs and support optimised prescribing.
	<b>Health economics</b>		
21	Establish processes to undertake de-novo health economic modelling to support AWTTTC outputs.		To provide a transparent, consistent and efficient approach to de-novo modelling across the various AWTTTC programmes of work.
22	Continue delivering health economic expertise to support value-focused decision making and priorities.		Value and cost-effectiveness continue to be considered in AWTTTC outputs aimed at delivering value for NHS Wales.

\* VPAG = Voluntary Scheme for Branded Medicines Pricing, Access, and Growth. Find out more here: [VPAG \(Wales\) Investment Programme – AWTTTC.nhs.wales](https://www.awtttc.nhs.uk/vpag)